PL2493930T3 - Udoskonalone przeciwciała przeciwko ludzkiej fraktalkinie i ich zastosowania - Google Patents

Udoskonalone przeciwciała przeciwko ludzkiej fraktalkinie i ich zastosowania

Info

Publication number: PL2493930T3
Authority: PL; Poland
Prior art keywords: fraktalkine; antibodies; improved anti; anti human; human
Prior art date: 2009-10-30

Application number

PL10826929T

Other languages

English (en)

Inventor

Miyuki Nishimura

Yoshimasa Sakamoto

Tetsu Kawano

Toshio Imai

Original Assignee

Eisai R&D Management Co., Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-10-30

Filing date

2010-10-28

Publication date

2019-03-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43922220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2493930(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-10-28 Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.

2019-03-29 Publication of PL2493930T3 publication Critical patent/PL2493930T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL10826929T 2009-10-30 2010-10-28 Udoskonalone przeciwciała przeciwko ludzkiej fraktalkinie i ich zastosowania PL2493930T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US25652109P	2009-10-30	2009-10-30
PCT/JP2010/069653 WO2011052799A1 (en)	2009-10-30	2010-10-28	Compositions and methods for treating inflammatory disorders
EP10826929.1A EP2493930B1 (en)	2009-10-30	2010-10-28	Improved anti human Fraktalkine antibodies and uses thereof

Publications (1)

Publication Number	Publication Date
PL2493930T3 true PL2493930T3 (pl)	2019-03-29

Family

ID=43922220

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL10826929T PL2493930T3 (pl)	2009-10-30	2010-10-28	Udoskonalone przeciwciała przeciwko ludzkiej fraktalkinie i ich zastosowania

Country Status (33)

Country	Link
US (1)	US8932592B2 (pl)
EP (1)	EP2493930B1 (pl)
JP (2)	JP5631991B2 (pl)
KR (2)	KR102099596B1 (pl)
CN (1)	CN102597003B (pl)
AR (2)	AR078796A1 (pl)
AU (1)	AU2010312408B2 (pl)
BR (1)	BR112012010266A2 (pl)
CA (1)	CA2778895C (pl)
CL (2)	CL2012001143A1 (pl)
CY (1)	CY1121167T1 (pl)
DK (1)	DK2493930T3 (pl)
ES (1)	ES2698389T3 (pl)
HR (1)	HRP20181973T1 (pl)
HU (1)	HUE041952T2 (pl)
IL (1)	IL219470A (pl)
JO (1)	JO3437B1 (pl)
LT (1)	LT2493930T (pl)
MX (1)	MX2012005052A (pl)
MY (1)	MY158481A (pl)
NZ (1)	NZ599779A (pl)
PE (1)	PE20121645A1 (pl)
PH (1)	PH12012500828A1 (pl)
PL (1)	PL2493930T3 (pl)
PT (1)	PT2493930T (pl)
RS (1)	RS58142B1 (pl)
RU (1)	RU2569109C2 (pl)
SI (1)	SI2493930T1 (pl)
SM (1)	SMT201800637T1 (pl)
TW (1)	TWI414308B (pl)
UA (1)	UA105073C2 (pl)
WO (1)	WO2011052799A1 (pl)
ZA (1)	ZA201203002B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9415118B2 (en) *	2013-03-13	2016-08-16	Novartis Ag	Antibody drug conjugates
ES2826566T3 (es)	2014-11-21	2021-05-18	Bristol Myers Squibb Co	Anticuerpos que comprenden regiones constantes pesadas modificadas
JP6805142B2 (ja)	2014-11-21	2020-12-23	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Ｃｄ７３に対する抗体およびその使用
EP3159007A1 (en)	2015-10-19	2017-04-26	Eisai R&D Management Co., Ltd.	Pharmaceutical composition for treating rheumatoid arthritis
JP2017154975A (ja) *	2016-02-29	2017-09-07	エーザイ・アール・アンド・ディー・マネジメント株式会社	クローン病を治療するための医薬組成物
JP2018070473A (ja) *	2016-10-26	2018-05-10	エーザイ・アール・アンド・ディー・マネジメント株式会社	関節リウマチを治療するための医薬組成物
JP2018177701A (ja) *	2017-04-14	2018-11-15	エーザイ・アール・アンド・ディー・マネジメント株式会社	クローン病を治療するための医薬組成物
US20220196674A1 (en) *	2019-04-17	2022-06-23	Abdolamir Landi	Treatment of autoimmune liver disease
CN113710272A (zh) *	2019-04-23	2021-11-26	卫材R&D管理有限公司	用于治疗类风湿性关节炎的生物标记物
CA3161271A1 (en) *	2019-12-09	2021-06-17	Alexion Pharmaceuticals, Inc.	Anti-c5 antibody for the treatment of neuromyelitis optica spectrum disorder
CN113087795B (zh) *	2019-12-23	2025-06-10	上海普铭生物科技有限公司	针对趋化因子cx3cl1的抗体及其应用
WO2022092183A1 (ja)	2020-10-30	2022-05-05	エーザイ・アール・アンド・ディー・マネジメント株式会社	医薬組成物
CN121537534B (zh) *	2026-01-22	2026-04-07	华中科技大学同济医学院附属协和医院	靶向cx3cl1的嵌合抗原受体-巨噬细胞及在gjb2突变相关遗传性耳聋治疗中的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI903489A7 (fi)	1988-11-11	1990-07-10	Medical Res Council	Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US6291158B1 (en)	1989-05-16	2001-09-18	Scripps Research Institute	Method for tapping the immunological repertoire
US6172197B1 (en)	1991-07-10	2001-01-09	Medical Research Council	Methods for producing members of specific binding pairs
US5397703A (en)	1992-07-09	1995-03-14	Cetus Oncology Corporation	Method for generation of antibodies to cell surface molecules
AU691811B2 (en) *	1993-06-16	1998-05-28	Celltech Therapeutics Limited	Antibodies
US6180377B1 (en)	1993-06-16	2001-01-30	Celltech Therapeutics Limited	Humanized antibodies
US6114507A (en)	1995-06-30	2000-09-05	Mochida Pharmaceutical Co., Ltd.	Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
US6096312A (en)	1995-06-30	2000-08-01	Mochida Pharmaceutical Co., Ltd.	Agent for suppressing a reduction of CD4+ lymphocytes
NZ311174A (en) *	1995-06-30	1999-04-29	Mochida Pharm Co Ltd	Anti-fas ligand antibody which suppresses fas ligand-induced apoptosis in cells and method of assaying a fas ligand using the anti-fas ligand antibody
US6548654B1 (en)	1996-01-24	2003-04-15	Schering Corporation	DNA encoding mammalian CX3C chemokine genes
JPH11503030A (ja)	1996-01-24	1999-03-23	シェーリングコーポレイション	哺乳動物ｃｘ３ｃケモカイン遺伝子
US7115379B1 (en)	1996-01-24	2006-10-03	Schering Corporation	Anti-mammalian CX3C cytokine antibodies
US6566503B2 (en)	1996-01-24	2003-05-20	Schering Corporation	Mammalian CX3C chemokine
US6043086A (en) *	1996-05-07	2000-03-28	Millenium Biotherapeutics, Inc.	Neurotactin and uses therefor
WO1997042224A1 (en)	1996-05-07	1997-11-13	Millennium Biotherapeutics, Inc.	Neurotactin and uses therefor
SE9802729D0 (sv)	1998-08-13	1998-08-13	Astra Pharma Prod	Novel Compounds
AU771946B2 (en)	1998-08-31	2004-04-08	Oregon Health And Science University	Prevention of cell migration initiation with CMV US28 receptor antagonists
JP2001218581A (ja)	1999-11-30	2001-08-14	Eisai Co Ltd	モノクローナル抗体の作製法
US6677321B1 (en)	1999-12-09	2004-01-13	Bruce Levin	Methods and compositions for treatment of inflammatory disease
AU2000273378A1 (en)	2000-02-18	2001-08-27	Millennium Pharmaceuticals, Inc.	Therapeutic methods that target fractalkine or cx3cr1
US8647612B2 (en)	2008-03-05	2014-02-11	Encore Health, Llc	Dithiol compounds, derivatives, and treatment of presbyopia
JP4263391B2 (ja)	2001-03-19	2009-05-13	エーザイ・アール・アンド・ディー・マネジメント株式会社	抗ｃｘ３ｃｒ１抗体、抗フラクタルカイン抗体及びフラクタルカインの利用
US20020192212A1 (en)	2001-03-19	2002-12-19	Toshio Imai	Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine
SE0101082D0 (sv)	2001-03-27	2001-03-27	Astrazeneca Ab	Novel use
US6821998B2 (en)	2001-08-30	2004-11-23	Chemocentryx, Inc.	Arylamines as inhibitors of chemokine binding to US28
EP1556053A4 (en)	2002-10-31	2006-04-19	Amgen Inc	ANTI-INFLAMMATORY AGENTS
TWI306458B (en) *	2003-05-30	2009-02-21	Elan Pharma Int Ltd	Humanized antibodies that recognize beta amyloid peptide
EP1520586A1 (en)	2003-09-30	2005-04-06	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Inhibition of fractalkine or of its receptor for the treatment of atopic allergic diseases
EP1671648A4 (en)	2003-10-02	2009-07-08	Eisai R&D Man Co Ltd	PREVENTION AND TREATMENT OF GVHD
WO2005033115A1 (en)	2003-10-07	2005-04-14	Astrazeneca Ab	New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1
JP4958555B2 (ja)	2004-09-22	2012-06-20	協和発酵キリン株式会社	安定化されたヒトＩｇＧ４抗体
EP1806145B1 (en) *	2004-10-29	2017-08-16	Eisai R&D Management Co., Ltd.	Remedy for inflammatory diseases
UA90707C2 (en)	2005-04-06	2010-05-25	Астразенека Аб	Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
AR053347A1 (es)	2005-04-06	2007-05-02	Astrazeneca Ab	Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
WO2008052108A2 (en) *	2006-10-26	2008-05-02	Centocor Ortho Biotech Inc.	Methods for use in human-adapting monoclonal antibodies
JP5963341B2 (ja) *	2007-09-14	2016-08-10	アムジエン・インコーポレーテツド	均質な抗体集団

2010
- 2010-10-27 JO JOP/2010/0374A patent/JO3437B1/ar active
- 2010-10-28 AU AU2010312408A patent/AU2010312408B2/en active Active
- 2010-10-28 BR BR112012010266A patent/BR112012010266A2/pt not_active Application Discontinuation
- 2010-10-28 LT LTEP10826929.1T patent/LT2493930T/lt unknown
- 2010-10-28 PH PH1/2012/500828A patent/PH12012500828A1/en unknown
- 2010-10-28 RU RU2012122203/10A patent/RU2569109C2/ru active
- 2010-10-28 KR KR1020167014386A patent/KR102099596B1/ko active Active
- 2010-10-28 US US13/504,742 patent/US8932592B2/en active Active
- 2010-10-28 PL PL10826929T patent/PL2493930T3/pl unknown
- 2010-10-28 RS RS20181424A patent/RS58142B1/sr unknown
- 2010-10-28 SM SM20180637T patent/SMT201800637T1/it unknown
- 2010-10-28 EP EP10826929.1A patent/EP2493930B1/en active Active
- 2010-10-28 TW TW099137131A patent/TWI414308B/zh active
- 2010-10-28 CN CN201080049138.0A patent/CN102597003B/zh active Active
- 2010-10-28 PE PE2012000580A patent/PE20121645A1/es active IP Right Grant
- 2010-10-28 HU HUE10826929A patent/HUE041952T2/hu unknown
- 2010-10-28 KR KR1020127014048A patent/KR101627605B1/ko active Active
- 2010-10-28 MY MYPI2012001924A patent/MY158481A/en unknown
- 2010-10-28 DK DK10826929.1T patent/DK2493930T3/en active
- 2010-10-28 PT PT10826929T patent/PT2493930T/pt unknown
- 2010-10-28 ES ES10826929T patent/ES2698389T3/es active Active
- 2010-10-28 MX MX2012005052A patent/MX2012005052A/es active IP Right Grant
- 2010-10-28 HR HRP20181973TT patent/HRP20181973T1/hr unknown
- 2010-10-28 NZ NZ599779A patent/NZ599779A/en not_active IP Right Cessation
- 2010-10-28 WO PCT/JP2010/069653 patent/WO2011052799A1/en not_active Ceased
- 2010-10-28 AR ARP100103947A patent/AR078796A1/es active IP Right Grant
- 2010-10-28 SI SI201031803T patent/SI2493930T1/sl unknown
- 2010-10-28 CA CA2778895A patent/CA2778895C/en active Active
- 2010-10-28 JP JP2012520621A patent/JP5631991B2/ja active Active
- 2010-10-28 UA UAA201206559A patent/UA105073C2/uk unknown
2012
- 2012-04-24 ZA ZA2012/03002A patent/ZA201203002B/en unknown
- 2012-04-29 IL IL219470A patent/IL219470A/en active IP Right Grant
- 2012-04-30 CL CL2012001143A patent/CL2012001143A1/es unknown
2014
- 2014-09-18 JP JP2014189668A patent/JP2015027304A/ja not_active Abandoned
2015
- 2015-01-15 CL CL2015000114A patent/CL2015000114A1/es unknown
2017
- 2017-09-15 AR ARP170102555A patent/AR109533A2/es unknown
2018
- 2018-11-29 CY CY20181101274T patent/CY1121167T1/el unknown

Also Published As

Publication number	Publication date
AU2010312408A1 (en)	2012-06-21
KR101627605B1 (ko)	2016-06-07
SMT201800637T1 (it)	2019-01-11
EP2493930A4 (en)	2013-12-04
KR102099596B1 (ko)	2020-04-10
SI2493930T1 (sl)	2018-12-31
US8932592B2 (en)	2015-01-13
IL219470A (en)	2017-10-31
MX2012005052A (es)	2012-05-29
ES2698389T3 (es)	2019-02-04
RU2012122203A (ru)	2013-12-10
CA2778895C (en)	2018-08-07
CA2778895A1 (en)	2011-05-05
EP2493930A1 (en)	2012-09-05
WO2011052799A1 (en)	2011-05-05
MY158481A (en)	2016-10-14
CN102597003A (zh)	2012-07-18
PT2493930T (pt)	2018-11-29
RU2569109C2 (ru)	2015-11-20
CY1121167T1 (el)	2020-05-29
HUE041952T2 (hu)	2019-06-28
RS58142B1 (sr)	2019-02-28
AU2010312408B2 (en)	2015-07-09
ZA201203002B (en)	2013-06-26
CL2015000114A1 (es)	2015-04-10
CL2012001143A1 (es)	2012-10-05
KR20160066055A (ko)	2016-06-09
UA105073C2 (uk)	2014-04-10
JP2015027304A (ja)	2015-02-12
AR109533A2 (es)	2018-12-19
LT2493930T (lt)	2019-01-10
US20120213799A1 (en)	2012-08-23
NZ599779A (en)	2014-03-28
JO3437B1 (ar)	2019-10-20
BR112012010266A2 (pt)	2016-12-06
PE20121645A1 (es)	2012-12-06
KR20120104560A (ko)	2012-09-21
IL219470A0 (en)	2012-06-28
JP5631991B2 (ja)	2014-11-26
JP2013509158A (ja)	2013-03-14
PH12012500828A1 (en)	2013-01-07
EP2493930B1 (en)	2018-09-19
AR078796A1 (es)	2011-12-07
DK2493930T3 (en)	2018-12-17
HRP20181973T1 (hr)	2019-01-25
TW201127401A (en)	2011-08-16
CN102597003B (zh)	2016-03-23
TWI414308B (zh)	2013-11-11

Publication	Publication Date	Title
EP2494062A4 (en)	2013-05-29	ANTI-GLP-1R ANTIBODIES AND THEIR USES
ZA201107486B (en)	2012-06-27	Anti-tnf-x antibodies and their uses
IL250624B (en)	2018-02-28	Anti-fgfr3 antibodies and methods of using them
SI2493930T1 (sl)	2018-12-31	Izboljšana protitelesa proti humanemu fraktalkinu in njihova uporaba
GB0922434D0 (en)	2010-02-03	antibodies and fragments thereof
IL216304A0 (en)	2012-01-31	Blocking anti- dkk-1 antibodies and their uses
IL215291A0 (en)	2011-12-29	NOVEL ANTI-a5BETA1 ANTIBODIES AND USES THEREOF
SMT202100676T1 (it)	2022-01-10	Anticorpi anti-cd277 e loro usi
ZA201107555B (en)	2012-12-27	Anti-17f antibodies and methods of use thereof
IL220536A0 (en)	2012-08-30	Anti - bv8 antibodies and uses thereof
GB0807018D0 (en)	2008-05-21	Antibodies and treatment
IL214355A0 (en)	2011-09-27	Antibodies against human tweak and uses thereof
GB0903151D0 (en)	2009-04-08	Antibody uses and methods
IL214527A0 (en)	2011-09-27	Anti-mst1r antibodies and uses thereof
IL219136A0 (en)	2012-06-28	Anti-hepsin antibodies and methods using same
IL216440A0 (en)	2012-02-29	Antibodies against human ccn1 and uses thereof
GB0906115D0 (en)	2009-05-20	Antibody and uses thereof
GB0911407D0 (en)	2009-08-12	Antibody and diagnostic use